Arrayit Corporation Approved for Direct Medicare Billing by the Centers for Medicare and Medicaid Services
September 10 2018 - 5:30AM
Sunnyvale, Sept. 10, 2018 (GLOBE NEWSWIRE) -- September 10, 2018
- Sunnyvale, CA – Arrayit Corporation (OTC: ARYC), a life sciences
and personalized medicine company, announces that Arrayit’s
proprietary finger stick allergy microarray test has been approved
for direct Medicare billing by the Centers for Medicare and
Medicaid Services (CMS). The Medicare national health
insurance program provides health insurance to more than 55 million
Americans annually, including 46 million seniors and 9 million
younger people. CMS projects a 2018 Medicare budget of
approximately $705,000,000,000 ($705 billion dollars), representing
about 17% of total federal spending.
Arrayit recently completed an allergy testing pilot program for
a top retail chain, established a nationwide network of 1,700
allergy sales professionals, met with top officials at the United
States Food and Drug Administration (FDA) regarding FDA approval of
a major product line, reported the sale of clinical instrumentation
to the FDA, signed allergy testing contracts with a consortium of
178 medical clinics, received approval for in-store promotions by a
major retailer, and announced allergy testing partnerships with
major allergy therapeutics providers. The new Medicare
billing entitlement allows doctors to prescribe Arrayit’s allergy
test to a significantly expanded number of patients.
Arrayit CEO Rene Schena states, “Our mission of making allergy
testing more accessible is facilitated by the direct Medicare
billing entitlement, which makes it easier for doctors to prescribe
the test to a larger patient population including seniors and young
people. The inherent coupling of preventative non-invasive
allergy testing with personalized precision medicine allows doctors
to leverage and recommend medicines, immunotherapy and lifestyle
changes to better manage allergy and asthma.”
About Arrayit
Arrayit Corporation, headquartered in Sunnyvale, California, leads
and empowers the research, biotechnology, pharmaceutical, clinical
and healthcare sectors through the discovery, development and
manufacture of proprietary life science and personalized medicine
products and services to advance biomedical research and improve
wellness and human health. Please visit www.arrayit.com for
more information.
Safe Harbor Statement
We have identified forward-looking statements by using words such
as "expect", "believe", and "should". Although we believe our
expectations are reasonable, our operations involve a number of
risks and uncertainties that are beyond our control, and these
statements may turn out not to be true. Risk factors associated
with our business, including some of the facts set forth herein,
are detailed in the Company's public filings.
CONTACT
Public Relations
Arrayit Corporation
Tel: 408-744-1331
Email: arrayit@arrayit.com
Web: www.arrayit.com
Public Relations
Arrayit Corporation
Tel: 408-744-1331
Email: arrayit@arrayit.com
Web: www.arrayit.com
Arrayit (CE) (USOTC:ARYC)
Historical Stock Chart
From Oct 2024 to Nov 2024
Arrayit (CE) (USOTC:ARYC)
Historical Stock Chart
From Nov 2023 to Nov 2024
